NasdaqGS:EXELBiotechs
Exelixis (EXEL) Stock Still Looks Like A Bargain On Earnings
Exelixis stock has quietly stacked up a strong share price record over the past five years, yet the current valuation checks still suggest the market may not be fully pricing in its fundamentals.
Exelixis has returned 228.6% over five years, which puts a spotlight on whether the current share price fairly reflects that track record.
Expectations around the durability of its revenue and cash flow from oncology treatments can support the current valuation, while any setback in clinical...